153 related articles for article (PubMed ID: 25768317)
1. Efficacy and safety of stereotactic ablative radiotherapy in patients with previous pneumonectomy.
Giaj Levra N; Filippi AR; Guarneri A; Badellino S; Mantovani C; Ruffini E; Ricardi U
Tumori; 2015; 101(2):148-53. PubMed ID: 25768317
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
5. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy in patients with previous pneumonectomy: safety and efficacy.
Thompson R; Giuliani M; Yap ML; Atallah S; Le LW; Sun A; Brade A; Cho BC; Bezjak A; Hope A
J Thorac Oncol; 2014 Jun; 9(6):843-7. PubMed ID: 24828663
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical experience of high-dose ablative lung radiotherapy: high pre-treatment [18F]fluorodeoxyglucose-positron emission tomography maximal standardized uptake value of the primary tumor adversely affects treatment outcome.
Lee DS; Kim YS; Yoo IeR; Kang YN; Kim SJ; Oh JK; Kim YK; Wang YP; Park JG; Kang JH; Han DH; Ahn MI; Lee KY
Lung Cancer; 2013 May; 80(2):172-8. PubMed ID: 23489556
[TBL] [Abstract][Full Text] [Related]
9. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).
Palma DA; Nguyen TK; Kwan K; Gaede S; Landis M; Malthaner R; Fortin D; Louie AV; Frechette E; Rodrigues GB; Yaremko B; Yu E; Dar AR; Lee TY; Gratton A; Warner A; Ward A; Inculet R
Radiat Oncol; 2017 Jan; 12(1):30. PubMed ID: 28129789
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
11. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
13. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
[TBL] [Abstract][Full Text] [Related]
16. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
[TBL] [Abstract][Full Text] [Related]
17. Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors.
Binkley MS; Shrager JB; Chaudhuri A; Popat R; Maxim PG; Shultz DB; Diehn M; Loo BW
Radiat Oncol; 2016 Mar; 11():40. PubMed ID: 26975700
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery.
Griffioen GH; Lagerwaard FJ; Haasbeek CJ; Smit EF; Slotman BJ; Senan S
Radiother Oncol; 2013 Jun; 107(3):403-8. PubMed ID: 23746675
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
[TBL] [Abstract][Full Text] [Related]
20. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
